Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 278-283, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (39)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, D. C.
Right arrow Articles by Redgrave, T. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, D. C.
Right arrow Articles by Redgrave, T. G.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:278-283.)
© 2002 American Association for Clinical Chemistry, Inc.

Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity

Dick C. Chan1, Gerald F. Watts1a, P. Hugh Barrett1, John C.L. Mamo2 and Trevor G. Redgrave3

1 Department of Medicine, University of Western Australia, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847 Australia.

2 Department of Nutrition, Dietetics and Food Sciences, Curtin University of Technology, GPO Box U1987, Perth, WA 6845 Australia.

3 Department of Physiology, University of Western Australia, 35 Stirling Highway, Crawley, Perth, WA 6009 Australia.

aAuthor for correspondence. Fax 61-8-9224-246; e-mail gfwatts{at}cyllene.uwa.edu.au.

Background: Triglyceride-rich lipoprotein remnants are atherogenic, and this may be particularly important in visceral obesity. We investigated remnant metabolism in obese men by measuring remnant-like particle-cholesterol (RLP-C), apolipoprotein (apo) B-48, apoC-III, and the clearance of a labeled remnant-like emulsion.

Methods: Fasting RLP-C, apoB-48, and apoC-III concentrations were measured in 48 viscerally obese men and 10 lean controls. RLP-C was determined by immunoseparation assay, apoB-48 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and enhanced chemiluminescence, and apoC-III by immunoturbidimetric assay. The catabolism of chylomicron remnants was measured by intravenous injection of a remnant-like emulsion containing cholesteryl [13C]oleate, with isotopic enrichment of 13CO2 in breath determined by isotope-ratio mass spectrometry and a multicompartmental model to estimate fractional catabolic rate (FCR) of the emulsion.

Results: Compared with controls, obese men had significantly increased plasma concentrations of RLP-C, apoB-48, and apoC-III (P <0.001 for all). Plasma total apoB-100, non-HDL-cholesterol, LDL-cholesterol, triglycerides, and insulin resistance (HOMA score) were also significantly higher in the obese group (P <0.001 for all). Obese men had a significantly lower FCR of the remnant-like emulsion compared with controls (P = 0.020).

Conclusions: Viscerally obese individuals have insulin resistance and increased plasma concentrations of triglyceride-rich lipoprotein remnants, which may be attributable to decreased catabolism of these particles.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Nutr.Home page
A. M. J. van Hees, W. H. M. Saris, G. M. Dallinga-Thie, G. B. Hul, J. A. Martinez, J.-M. Oppert, V. Stich, A. Astrup, P. Arner, T. I. A. Sorensen, et al.
Fasting and Postprandial Remnant-Like Particle Cholesterol Concentrations in Obese Participants Are Associated with Plasma Triglycerides, Insulin Resistance, and Body Fat Distribution
J. Nutr., December 1, 2008; 138(12): 2399 - 2405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. G. Scheffer, T. Teerlink, J. M. Dekker, G. Bos, G. Nijpels, M. Diamant, P. J. Kostense, C. D. A. Stehouwer, and R. J. Heine
Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study
Clin. Chem., August 1, 2008; 54(8): 1325 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong
PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E421 - E434.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. C. Chan, G. F. Watts, M. N. Nguyen, and P. H. R. Barrett
Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 590 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. C. Chan, G. F. Watts, T. W.K. Ng, Y. Uchida, N. Sakai, S. Yamashita, and P. H. R. Barrett
Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism
Clin. Chem., March 1, 2005; 51(3): 578 - 585.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
A. Harbis, S. Perdreau, S. Vincent-Baudry, M. Charbonnier, M.-C. Bernard, D. Raccah, M. Senft, A.-M. Lorec, C. Defoort, H. Portugal, et al.
Glycemic and insulinemic meal responses modulate postprandial hepatic and intestinal lipoprotein accumulation in obese, insulin-resistant subjects
Am. J. Clinical Nutrition, October 1, 2004; 80(4): 896 - 902.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. A. Brinton, M. N. Nanjee, and P. N. Hopkins
Triglyceride-rich lipoprotein remnant levels and metabolism: Time to adopt these orphan risk factors?
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2233 - 2235.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Bos, P. G. Scheffer, D. Vieira, J. M. Dekker, G. Nijpels, M. Diamant, T. Teerlink, C. D.A. Stehouwer, L. M. Bouter, R. J. Heine, et al.
The Relationship of Lipoprotein Lipase Activity and LDL size Is Dependent on Glucose Metabolism in an Elderly Population: The Hoorn Study
Diabetes Care, March 1, 2004; 27(3): 796 - 798.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
J. Lipid Res., December 1, 2003; 44(12): 2374 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. C Chan, G. F Watts, T. A Mori, P H. R Barrett, T. G Redgrave, and L. J Beilin
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity
Am. J. Clinical Nutrition, February 1, 2003; 77(2): 300 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. R. Blackett, R. Germany, B. Sambo, and P. Alaupovic
Apolipoprotein C-III Bound to Apolipoprotein B-containing Lipoproteins in Obese Girls
Clin. Chem., February 1, 2003; 49(2): 303 - 306.
[Full Text] [PDF]

Home page
 DiabetesHome page
D. C. Chan, G. F. Watts, P. H. R. Barrett, L. J. Beilin, T. G. Redgrave, and T. A. Mori
Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia
Diabetes, August 1, 2002; 51(8): 2377 - 2386.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Jialal and S. Devaraj
Remnant Lipoproteins: Measurement and Clinical Significance
Clin. Chem., February 1, 2002; 48(2): 217 - 219.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.